Lapatinib ditosylate: Expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer

Drugs of Today

Volumn 47, Issue 5, 2011, Pages 335-345

  Awada, Ahmad ^a   Saliba, W ^a   Bozovic Spasojevic, I ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LAPATINIB; LETROZOLE; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

BRAIN METASTASIS; BREAST CANCER; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INFLAMMATORY BREAST CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOADJUVANT THERAPY; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 80052778547     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.5.1584110     Document Type: Review

References (33)

1. Perou, C.M., Sorlie, T., Eisen, M.B. et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797): 747-52.
2. Ross, J.S. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect 2009, 22(2): 93-106.
3. Konecny, G.E., Pegram, M.D., Venkatesan, N. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66(3): 1630-9.
4. Wood, E.R., Truesdale, A.T., McDonald, O.B. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004, 64(18): 6652-9.
5. Rusnak, D.W., Lackey, K., Affleck, K. et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001, 1(2): 85-94.
6. Geyer, C.E., Forster, J., Lindquist, D. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26): 2733-43.
7. Di Leo, A., Gomez, H.L., Aziz, Z. et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26(34): 5544-52.
8. Guan, Z.-z., Xu, B.-h., Arpornwirat, W. et al. Overall survival benefit observed with lapatinib (L) plus paclitaxel (P) as first-line therapy in patients with HER2-overexpressing metastatic breast cancer (MBC). Cancer Res [33rd Annu San Antonio Breast Cancer Symp (Dec 8-12, San Antonio) 2010] 2010, 70(24, Suppl.): Abst P3-14-24.
9. Blackwell, K.L., Burstein, H.J., Storniolo, A.M. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28(7): 1124-30.
10. Kaufman, B., Trudeau, M., Awada, A. et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009, 10(6): 581-8.
11. Lin, N.U., Dieras, V., Paul, D. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15(4): 1452-9.
12. Baselga, J., Bradbury, I., Eidtmann, H. et al. First results of the NeoALTTO trial (BIG 01-06 / EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res [33rd Annu San Antonio Breast Cancer Symp (Dec 8-12, San Antonio) 2010] 2010, 70(24, Suppl.): Abst S3-3.
13. Untch, M., Loibl, S., Bischoff, J. et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline- taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44). Cancer Res [33rd Annu San Antonio Breast Cancer Symp (Dec 8-12, San Antonio) 2010] 2010, 70(24, Suppl.): Abst S3-1.
14. Burris, H.A., 3rd, Hurwitz, H.I., Dees, E.C. et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23(23): 5305-13.
15. Gomez, H.L., Doval, D.C., Chavez, M.A. et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008, 26(18): 2999-3005.
16. Leyland-Jones, B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009, 27(31): 5278-86.
17. Schwartzberg, L.S., Franco, S.X., Florance, A., O'Rourke, L., Maltzman, J., Johnston, S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010, 15(2): 122-9.
18. Johnston, S., Pippen, J., Jr., Pivot, X. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(33): 5538-46.
19. Kaufman, B., Mackey, J.R., Clemens, M.R. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27(33): 5529-37.
20. Lenferink, A.E., Simpson, J.F., Shawver, L.K., Coffey, R.J., Forbes, J.T., Arteaga, C.L. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci U S A 2000, 97(17): 9609-14.
21. Cameron, D., Casey, M., Press, M. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112(3): 533-43.
22. Gianni, L., Pienkowski, T., Im, Y.-H. et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Cancer Res [33rd Annu San Antonio Breast Cancer Symp (Dec 8-12, San Antonio) 2010] 2010, 70(24, Suppl.): Abst S3-2.
23. ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D (NCT00490139). ClinicalTrials.gov, Accessed May 6, 2011.
24. Guarneri, V., Frassoldati, A., Piacentini, F., Jovic, G., Giovannelli, S., Oliva, C., Conte, P. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). Clin Breast Cancer 2008, 8(2): 192-4.
25. Preoperative chemotherapy with paclitaxel, gemcitabine, and lapatinib (Tykerb® ) (PGT) (NCT01133912). ClinicalTrials.gov Web site, Accessed May 6, 2011.
26. Paclitaxel and trastuzumab and/or lapatinib in treating patients with stage II or stage III breast cancer that can be removed by surgery (NCT00770809). ClinicalTrials.gov Web site, Accessed May 6, 2011.
27. Lapatinib +/- trastuzumab in addition to standard neoadjuvant breast cancer therapy (NCT00524303). ClinicalTrials.gov Web site, Accessed May 6, 2011.
28. Tykerb evaluation after chemotherapy (TEACH): Lapatinib versus placebo in women with early-stage breast cancer (NCT00374322). ClinicalTrials.gov, Accessed May 6, 2011.
29. Complete study: Chemotherapy and lapatinib or trastuzumab in treating women with HER2/Neu-positive metastatic breast cancer (NCT00667251). ClinicalTrials.gov Web site, Accessed May 6, 2011.
30. Lapatinib in combination with vinorelbine (VITAL) (NCT01013740). ClinicalTrials.gov Web site, Accessed May 6, 2011.
31. Cerebel study: Lapatinib plus capecitabine versus trastuzumab plus capecitabine in ErbB2 (HER2) positive metastatic breast cancer (NCT00820222). ClinicalTrials.gov Web site, Accessed May 6, 2011.
32. Continued HER2 suppression with lapatinib plus trastuzumab versus trastuzumab alone (NCT00968968). ClinicalTrials.gov Web site, Accessed May 6, 2011.
33. A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (NCT01160211). ClinicalTrials.gov Web site, Accessed May 6, 2011.